Review





Similar Products

xl184 ind  (Exelixis)
86
Exelixis xl184 ind
Xl184 Ind, supplied by Exelixis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xl184/fda_document____drugsatfda_docs_slash_nda_slash_2016_slash_208692orig1s000admincorres-1272-20-28?v=Exelixis
Average 86 stars, based on 1 article reviews
xl184 ind - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
xl184  (Exelixis)
86
Exelixis xl184
Xl184, supplied by Exelixis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xl184/fda_document____drugsatfda_docs_slash_nda_slash_2016_slash_208692orig1s000admincorres-1334-9-23?v=Exelixis
Average 86 stars, based on 1 article reviews
xl184 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
xl184 randomized  (Exelixis)
86
Exelixis xl184 randomized
Xl184 Randomized, supplied by Exelixis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xl184/fda_document____drugsatfda_docs_slash_nda_slash_2016_slash_208692orig1s000admincorres-1275-12-0?v=Exelixis
Average 86 stars, based on 1 article reviews
xl184 randomized - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
cabozantinib xl184 cabometyx bms-907351 cometriq  (Exelixis)
90
Exelixis cabozantinib xl184 cabometyx bms-907351 cometriq
Overview of type II AXL inhibitors and their current status in clinical trials for AML
Cabozantinib Xl184 Cabometyx Bms 907351 Cometriq, supplied by Exelixis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xl184/pmc11453060-33-0-8?v=Exelixis
Average 90 stars, based on 1 article reviews
cabozantinib xl184 cabometyx bms-907351 cometriq - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
cabozantinib xl184  (Exelixis)
90
Exelixis cabozantinib xl184
Overview of type II AXL inhibitors and their current status in clinical trials for AML
Cabozantinib Xl184, supplied by Exelixis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xl184/pm39128361-366-0-15?v=Exelixis
Average 90 stars, based on 1 article reviews
cabozantinib xl184 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
cabozantinib xl184 cabometyx/cometriq  (Exelixis)
90
Exelixis cabozantinib xl184 cabometyx/cometriq
Molecular structures and timeline of small molecule tyrosine kinase inhibitors approved for advanced hepatocellular carcinoma . First-line sorafenib, lenvatinib, and donafenib are shown above the timeline, second-line regorafenib, <t>cabozantinib,</t> and apatinib are shown below the timeline. Sorafenib, lenvatinib, regorafenib, and cabozantinib were firstly approved by US Food and Drug Administration, donafenib and apatinib were firstly approved by National Medical Products Administration (NMPA) of China
Cabozantinib Xl184 Cabometyx/Cometriq, supplied by Exelixis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xl184/pmc11222362-5-0-4?v=Exelixis
Average 90 stars, based on 1 article reviews
cabozantinib xl184 cabometyx/cometriq - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
cabo (previously known as xl184)  (Exelixis)
90
Exelixis cabo (previously known as xl184)
Molecular structures and timeline of small molecule tyrosine kinase inhibitors approved for advanced hepatocellular carcinoma . First-line sorafenib, lenvatinib, and donafenib are shown above the timeline, second-line regorafenib, <t>cabozantinib,</t> and apatinib are shown below the timeline. Sorafenib, lenvatinib, regorafenib, and cabozantinib were firstly approved by US Food and Drug Administration, donafenib and apatinib were firstly approved by National Medical Products Administration (NMPA) of China
Cabo (Previously Known As Xl184), supplied by Exelixis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/xl184/us11987598-473-25-10?v=Exelixis
Average 90 stars, based on 1 article reviews
cabo (previously known as xl184) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Overview of type II AXL inhibitors and their current status in clinical trials for AML

Journal: Experimental Hematology & Oncology

Article Title: AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

doi: 10.1186/s40164-024-00566-8

Figure Lengend Snippet: Overview of type II AXL inhibitors and their current status in clinical trials for AML

Article Snippet: Cabozantinib (XL184, Cabometyx, BMS-907351, Cometriq ® ) , Exelixis/Ipsen company , VEGFR2, MET, RET, KIT, AXL, FLT1/3/4 , 7 nM (in vitro), 42 nM (in cells) , Terminated phase Ib trial b (NCT03878524).

Techniques: Clinical Proteomics, In Vitro

Molecular structures and timeline of small molecule tyrosine kinase inhibitors approved for advanced hepatocellular carcinoma . First-line sorafenib, lenvatinib, and donafenib are shown above the timeline, second-line regorafenib, cabozantinib, and apatinib are shown below the timeline. Sorafenib, lenvatinib, regorafenib, and cabozantinib were firstly approved by US Food and Drug Administration, donafenib and apatinib were firstly approved by National Medical Products Administration (NMPA) of China

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: Molecular structures and timeline of small molecule tyrosine kinase inhibitors approved for advanced hepatocellular carcinoma . First-line sorafenib, lenvatinib, and donafenib are shown above the timeline, second-line regorafenib, cabozantinib, and apatinib are shown below the timeline. Sorafenib, lenvatinib, regorafenib, and cabozantinib were firstly approved by US Food and Drug Administration, donafenib and apatinib were firstly approved by National Medical Products Administration (NMPA) of China

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques:

Key clinical trials of small molecule receptor tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: Key clinical trials of small molecule receptor tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques: Clinical Proteomics

The outcomes of cabozantinib in retrospective and real-life studies

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: The outcomes of cabozantinib in retrospective and real-life studies

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques:

Ongoing clinical trials of TKIs and TKI-based combination therapies for advanced hepatocellular carcinoma

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: Ongoing clinical trials of TKIs and TKI-based combination therapies for advanced hepatocellular carcinoma

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques: Clinical Proteomics